ENTPD1 and myeloid sarcoma: MS patients that express low levels of CD39 are likely to respond to cladribine therapy, since they lack the level of immune-regulation provided by the generation of suppressive adenosine, and thus may benefit from pharmacologically induced increases in adenosine.